477 related articles for article (PubMed ID: 34731180)
1. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
[TBL] [Abstract][Full Text] [Related]
2. Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models.
Wicker CA; Hunt BG; Krishnan S; Aziz K; Parajuli S; Palackdharry S; Elaban WR; Wise-Draper TM; Mills GB; Waltz SE; Takiar V
Cancer Lett; 2021 Apr; 502():180-188. PubMed ID: 33450358
[TBL] [Abstract][Full Text] [Related]
3. Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
Meric-Bernstam F; Tannir NM; Iliopoulos O; Lee RJ; Telli ML; Fan AC; DeMichele A; Haas NB; Patel MR; Harding JJ; Voss MH; Owonikoko TK; Carthon B; Srinivasan R; Bendell JC; Jenkins Y; Whiting SH; Orford K; Bennett MK; Bauer TM
Clin Cancer Res; 2022 Apr; 28(8):1540-1548. PubMed ID: 35140121
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
Tannir NM; Agarwal N; Porta C; Lawrence NJ; Motzer R; McGregor B; Lee RJ; Jain RK; Davis N; Appleman LJ; Goodman O; Stadler WM; Gandhi S; Geynisman DM; Iacovelli R; Mellado B; Sepúlveda Sánchez JM; Figlin R; Powles T; Akella L; Orford K; Escudier B
JAMA Oncol; 2022 Oct; 8(10):1411-1418. PubMed ID: 36048457
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways.
Son JY; Yoon S; Tae IH; Park YJ; De U; Jeon Y; Park YJ; Rhyu IJ; Lee BM; Chung KH; Lim JE; Lee SJ; Lee HW; Kwak JH; Kim HS; Choi HY
Cancer Med; 2018 Oct; 7(10):5083-5095. PubMed ID: 30160042
[TBL] [Abstract][Full Text] [Related]
7. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
Matsuki M; Adachi Y; Ozawa Y; Kimura T; Hoshi T; Okamoto K; Tohyama O; Mitsuhashi K; Yamaguchi A; Matsui J; Funahashi Y
Cancer Sci; 2017 Apr; 108(4):763-771. PubMed ID: 28107584
[TBL] [Abstract][Full Text] [Related]
8. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY
BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839
[TBL] [Abstract][Full Text] [Related]
9. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice.
Boysen G; Jamshidi-Parsian A; Davis MA; Siegel ER; Simecka CM; Kore RA; Dings RPM; Griffin RJ
Int J Radiat Biol; 2019 Apr; 95(4):436-442. PubMed ID: 30557074
[TBL] [Abstract][Full Text] [Related]
10. Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging.
Abu Aboud O; Habib SL; Trott J; Stewart B; Liang S; Chaudhari AJ; Sutcliffe J; Weiss RH
Cancer Res; 2017 Dec; 77(23):6746-6758. PubMed ID: 29021138
[TBL] [Abstract][Full Text] [Related]
11. The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma.
Momcilovic M; Bailey ST; Lee JT; Fishbein MC; Braas D; Go J; Graeber TG; Parlati F; Demo S; Li R; Walser TC; Gricowski M; Shuman R; Ibarra J; Fridman D; Phelps ME; Badran K; St John M; Bernthal NM; Federman N; Yanagawa J; Dubinett SM; Sadeghi S; Christofk HR; Shackelford DB
Cancer Cell; 2018 May; 33(5):905-921.e5. PubMed ID: 29763624
[TBL] [Abstract][Full Text] [Related]
12. Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers.
Rashmi R; Jayachandran K; Zhang J; Menon V; Muhammad N; Zahner M; Ruiz F; Zhang S; Cho K; Wang Y; Huang X; Huang Y; McCormick ML; Rogers BE; Spitz DR; Patti GJ; Schwarz JK
Mol Cancer Ther; 2020 Dec; 19(12):2465-2475. PubMed ID: 33087507
[TBL] [Abstract][Full Text] [Related]
13. Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.
Lee CH; Motzer R; Emamekhoo H; Matrana M; Percent I; Hsieh JJ; Hussain A; Vaishampayan U; Liu S; McCune S; Patel V; Shaheen M; Bendell J; Fan AC; Gartrell BA; Goodman OB; Nikolinakos PG; Kalebasty AR; Zakharia Y; Zhang Z; Parmar H; Akella L; Orford K; Tannir NM
Clin Cancer Res; 2022 Aug; 28(15):3248-3255. PubMed ID: 35576438
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
Hirayama Y; Gi M; Yamano S; Tachibana H; Okuno T; Tamada S; Nakatani T; Wanibuchi H
Cancer Sci; 2016 Dec; 107(12):1736-1744. PubMed ID: 27712020
[TBL] [Abstract][Full Text] [Related]
16. The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.
Zou Y; Wang J; Leng X; Huang J; Xue W; Zhang J; Huang Y
Oncotarget; 2017 Mar; 8(13):20825-20833. PubMed ID: 28212559
[TBL] [Abstract][Full Text] [Related]
17. Targeting glutamine metabolism slows soft tissue sarcoma growth.
Lee P; Malik D; Perkons N; Huangyang P; Khare S; Rhoades S; Gong YY; Burrows M; Finan JM; Nissim I; Gade TPF; Weljie AM; Simon MC
Nat Commun; 2020 Jan; 11(1):498. PubMed ID: 31980651
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
D'Amato C; Rosa R; Marciano R; D'Amato V; Formisano L; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fulciniti F; Cipolletta A; Bianco C; Ciardiello F; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Sep; 111(6):1168-79. PubMed ID: 25093491
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of glutamine metabolism in acquired-EGFR-TKI-resistant lung cancer.
Kim S; Jeon JS; Choi YJ; Baek GH; Kim SK; Kang KW
Life Sci; 2022 Feb; 291():120274. PubMed ID: 34990648
[TBL] [Abstract][Full Text] [Related]
20. Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1
Shah R; Singh SJ; Eddy K; Filipp FV; Chen S
Cancer Res; 2019 Apr; 79(8):1799-1809. PubMed ID: 30987979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
